DM2 RENALITY

Nuevas dimensiones en enfermedad renal diabética

ERA-EDTA HIGHLIGHTS

13-16 de junio 2019

Dieta hipoproteica y suplementos basados en cuerpos cetónicos

Dra. María Marques

Con el patrocinio de:

mundipharma

Iniciativa científica de:

SOCIEDAD VALENCIANA DE NEFROLOGIA
SVN

era edta
LEADING EUROPEAN NEPHROLOGY

56th ERA-EDTA Congress

Held jointly with HUNGARIAN SOCIETY OF NEPHROLOGY

Budapest, Hungary
June 13th-16th, 2019

Ketoanalogue Supplementation Preserves Renal Function But Decline In Renal Function Is Observed After Withdrawing Supplementation - A Follow-up Study Of Randomized Clinical Trial

Anita Saxena[1], Amit Gupta[2], Trisha Sachan[3]
[1,2]Professor, [3]Research Fellow
Department of Nephrology
Sanjay Gandhi Post Graduate Institute Of Medical Sciences Lucknow India.


Group I Supplemented
Ketoanalogue (2 tablets TID
1 tab (365mg)/10kg bw)10 Months
Advised Very Low Protein Diet
Protein 0.4 g/kg Energy 35 kcal/kg
Visits And Evaluation
Group 2 Control
LPD 0.6 g/kg/d Protein
Energy 35 kcal/kg/d
Visit 1-Baseline
Supplementation for 10 months
Biochemical Profile: Hemoglobin, Serum Creatinine, Albumin , Sodium, Potassium Calcium, Phosphorus, Random Blood Glucose Anthropometry: Body weight, Height, BMI Nutritional Status Evaluated Subjective Global Assessment, 3 days Dietary Intake Dietician
Biochemical Profile: Hemoglobin, Serum Creatinine, Albumin , Sodium, Potassium Calcium, Phosphorus, Random Blood Glucose Anthropometry: Body weight, Height, BMI Nutritional Status Evaluated Subjective Global Assessment, 3 days Dietary Intake Dietician
Visit 2: 10 Months (±5days from V1)
Biochemical Profile
Subjective Global Assessment,
Dietary Intake
Compliance: Empty foils were returned
and Safety adverse events
Biochemical Profile
Subjective Global Assessment,
Dietary Intake
Compliance: Empty foils were returned
END OF INTERVENTION


Group I
Ketoanalogue Supplemented
Follow-Up Visits And Evaluation
After 10 Months Every 12 M till 58 months
Group 2 Control
Standard Low Protein Diet
Ketoanalogue Supplementation Stopped at 10 months
Protein 0.6 g/kg/d
Energy 35 kcal/kg/d
FU Visit 22 Months
0.6g/kg/d protein
35kcal/kg energy
Investigations: Biochemical Profile
Subjective Global Assessment,
3 days dietary recall
Visits at 34 ,46, 58
(Annual Visits)
Investigations: Biochemical Profile
Subjective Global Assessment,
3 days dietary recall
Investigations: Biochemical Profile
Subjective Global Assessment,
3 days dietary recall
Investigations: Biochemical Profile
Subjective Global Assessment,
3 days dietary recall
58 Months
END OF THE STUDY
Data were analyzed using SPSS windows Version 12

Repeated Measures ANOVA Showing Changes In Serum Creatinine in Supplemented and Control Groups From baseline to 10 Months and Follow-up till 58 Months

Lost 6 patients
Treatment Group:

1 died of lung infection
1 AKI Transplant
Controls :
4 Progressed to ESRD



Treatment Group : Decline in serum creatinine from baseline to 10 months indicating effect of supplementation .
After 10 months gradual increase to baseline and followed by steady increase .
Control Group: Gradual rise in serum cretinine from baseline

Repeated Measures ANOVA Showing Changes In GFR in Supplemented and Control Groups From baseline to 10 Months and Follow-up till 58 Months

Group	Baseline	10 Months	22 Months	34 Months	46 Months	58 Months
Treatment	46.71 ±13.45	45.12 ±14.38	42.98 ±13.35	37.86 ±16.91	39.60 ±20.46	36.34 ±18.96
Rate of Change in GFRml/minute with respect to BASELINE		1.59	-2.34	-12.08	-11.57	-19.30
Control	49.51 ±15.19	49.17 ±16.47	45.04 ±16.35	30.68 ±17.67	31.55 ±16.36	34.14 ±21.71
Drop in GFR ml with respect to BASELINE		-2.53	-6.39	-32.24	-39.50	-44.02



Annual Rate of Change In GFR From Baseline At 10, 22, 34, 46, 58 Months



Treatment Group : Increase in GFR from baseline till 10 months indicating effect of supplementation followed by gradual decline to baseline . Followed by gradual decline Control Group: continuous decline in GFR from baseline and transition into higher CKD stages.